Filing Details

Accession Number:
0000899243-23-019970
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-10-18 16:30:16
Reporting Period:
2023-10-16
Accepted Time:
2023-10-18 16:30:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1805387 Cerevel Therapeutics Holdings Inc. CERE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1432313 R Christopher Gordon C/O Bain Capital Investors, Llc
200 Clarendon Street
Boston MA 02116
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-10-16 5,480,052 $22.81 65,679,781 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,282 Direct
Footnotes
  1. Represents shares of the Issuer's common stock held directly by BC Perception Holdings, LP ("BC Perception"). Christopher Gordon is a Partner of Bain Capital Investors, LLC ("BCI"), the ultimate general partner of BC Perception. Voting and investment decisions with respect to securities held by BC Perception are made by the partners of BCI. As a result, Mr. Gordon may be deemed to share voting and dispositive power with respect to the securities held by BC Perception. Mr. Gordon disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
  2. On October 16, 2023, BC Perception purchased 5,480,052 shares of the Issuer's common stock at a price of $22.81 per share in an underwritten public offering.